

Appendix 3: Differences in absolute risks of harms in randomized trials and in each of the corresponding nonrandomized studies

Harm (intervention)	Randomized trials		Nonrandomized studies	
	Topic no.*	Risk difference (95% CI), %	Topic no.*	Risk difference (95% CI), %
Encephalopathy (acellular v. whole-cell pertussis vaccine)	1	0.00 (-0.01 to 0.01)	1a	-0.0001 (-0.0001 to 0.0000)
Convulsions (acellular v. whole-cell pertussis vaccine)	2	-0.04 (-0.07 to -0.01)	2a	-0.0010 (-0.0012 to -0.0008)
			2b	-0.0011 (-0.0013 to -0.0008)
Hepatitis-related death (isoniazid chemoprophylaxis)	9	0.02 (0.00 to 0.05)	9a	0.00 (0.00 to 0.03)
			9b	0.0011 (0.0000 to 0.0020)
Visceral or vascular injury (laparoscopy v. open surgery for inguinal hernia)	10	0.02 (-0.28 to 0.31)	10a	1.22 (-0.25 to 2.69)
Wound infection (laparoscopy v. open surgery for appendicitis)	11	-2.96 (-4.26 to -1.66)	11a	-1.32 (-2.20 to -0.44)
			11b	-2.80 (-3.00 to -2.60)
Spontaneous miscarriage (folate supplementation)	12	1.13 (-0.20 to 2.47)	12a	0.30 (-1.10 to 1.70)
			12b	1.30 (-0.30 to 2.90)
Multiple gestation (folate supplementation)	13	0.49 (-0.11 to 1.08)	13a	-0.06 (-0.12 to 0.00)
			13b	-0.15 (-0.97 to 0.67)
			13c	1.30 (0.65 to 1.95)
Major bleed (platelet glycoprotein IIB/IIIa blocker therapy in PCI)	14	0.96 (0.09 to 1.83)	14a	0.25 (-0.02 to 0.52)

Note: CI = confidence interval, PCI = percutaneous coronary intervention.

*The topic numbers correspond to those listed in Table 1 of the print article (available at www.cmaj.ca/cgi/content/full/174/5/635).